Development and initial validation of an instrument for video-based assessment of technical skill in ERCP - 17/03/21
on behalf of the
SVI study group and the U.S. Cooperative for Outcomes Research in Endoscopy
Abstract |
Background and Aims |
The accurate measurement of technical skill in ERCP is essential for endoscopic training, quality assurance, and coaching of this procedure. Hypothesizing that technical skill can be measured by analysis of ERCP videos, we aimed to develop and validate a video-based ERCP skill assessment tool.
Methods |
Based on review of procedural videos, the task of ERCP was deconstructed into its basic components by an expert panel that developed an initial version of the Bethesda ERCP Skill Assessment Tool (BESAT). Subsequently, 2 modified Delphi panels and 3 validation exercises were conducted with the goal of iteratively refining the tool. Fully crossed generalizability studies investigated the contributions of assessors, ERCP performance, and technical elements to reliability.
Results |
Twenty-nine technical elements were initially generated from task deconstruction. Ultimately, after iterative refinement, the tool comprised 6 technical elements and 11 subelements. The developmental process achieved consistent improvements in the performance characteristics of the tool with every iteration. For the most recent version of the tool, BESAT-v4, the generalizability coefficient (a reliability index) was .67. Most variance in BESAT scores (43.55%) was attributed to differences in endoscopists’ skill, indicating that the tool can reliably differentiate between endoscopists based on video analysis.
Conclusions |
Video-based assessment of ERCP skill appears to be feasible with a novel instrument that demonstrates favorable validity evidence. Future steps include determining whether the tool can discriminate between endoscopists of varying experience levels and predict important outcomes in clinical practice.
Le texte complet de cet article est disponible en PDF.Abbreviations : BESAT, D, G, SVI
Plan
| DISCLOSURE: Dr Elmunzer, Consultant for Takeda pharmaceuticals; Dr Elta, consultant for Olympus Medical; Dr Cote, consultant for Olympus Corporation and Boston Scientific, paid speaker/teacher for Abbvie Pharmaceuticals, research support from Kangen Pharmaceuticals and Boston Scientific Corporation; Dr Willingham, research funding from Cancer Prevention Pharmaceuticals, Cook Medical, Boston Scientific, and PCI Biotech; Dr Varadarajulu, consultant for Boston Scientifc, Olympus America, Medtronic, and Creo Medical. All other authors disclosed no financial relationships. Research support for this study was provided in part by National Institutes of Health grant U01DK104833. |
|
| If you would like to chat with an author of this article, you may contact Dr Elmunzer at elmunzer@musc.edu. |
Vol 93 - N° 4
P. 914-923 - avril 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
